Category: Psychedelic Bulletin - Page 9 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS

Post published:December 12, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas

Post published:December 4, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round

Post published:November 19, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A

Post published:November 11, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM

Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM

Post published:November 4, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022

Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022

Post published:October 28, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A

Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A

Post published:October 24, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR

Post published:September 30, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Post published:September 12, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics

Post published:September 6, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.